Journals / Türk Nöroşirürji Dergsi / 2019 / Cilt: 29 - Sayı: 3

Glioblastoma

Glioblastom

Pages
305–334
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The survival has improved but is still measured in years.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Glioblastoma (GBM) is the most common malignant tumor of the central nervous system and its treatment is complex and complicated in many aspects.
📊
Key Findings & Data:However a better understanding of tumor biology has enabled us to improve treatment, improve survival and increase the quality of life.
💡
Conclusion & Impact:The survival has improved but is still measured in years.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Glioblastoma (GBM) is the most common malignant tumor of the central nervous system and its treatment is complex and complicated in many aspects. Despite an extensive amount of information on this tumor, the treatment is still not curative. However a better understanding of tumor biology has enabled us to improve treatment, improve survival and increase the quality of life. Studies on tumor biology have made the diagnosis more objective and rational treatments possible. The current treatment relies on a combination of surgery, external beam radiotherapy and chemotherapy with alkylating agents. Recurrence is seen in all patients and in this instance treatment options are again surgery, radiotherapy, chemotherapy and antiangiogenic therapy with bevacuzimab. No other treatment has come into routine use. The survival has improved but is still measured in years.

Özet

Glioblastom (GBM) santral sinir sisteminin en sık görülen malin tümörüdür ve tedavisi her yönü ile kompleks ve zordur. Bu tümörkonusunda uzun yıllar içinde oluşan büyük bilgi birikimine rağmen halen küratif tedavi mümkün değildir. Fakat teknik ve teknolojikgelişmeler ve hastalık biyolojisini anlamamız sayesinde tedavi her zamankinden daha yüz güldürücü şekilde yapılabilmekte,hasta sağkalımı ve hayat kalitesi yüksek tutulabilmektedir. Tümör biyolojisi konusunda yapılan çalışmalar glioblastomların tanısınıdaha objektif hale getirmiş ve hastalık davranışını daha iyi anlayabilmemizi sağlamıştır. Günümüzde halen glioblastom tedavisininmerkezini cerrahi, radyoterapi ve alkilleyici ajanlarla uygulanan kemoterapi oluşturur. Rekürens tüm hastalarda izlenir ve bu durumdada cerrahi, radyoterapi, kemoterapi ve bevacuzimab ile antianjiyogenik tedavi uygulanır. Tüm diğer tedavi yöntemleri arasındastandart kullanıma girebilen bir yöntem olmamıştır. Sağkalım günümüzde düzelmiş olmasına rağmen hâlâ yıllarla ölçülür.

🔖

Cite This Article

PAMIR, M. N., ÖZDUMAN, K., HACIHANEFIOĞLU, M. (2022). Glioblastoma. Türk Nöroşirürji Dergsi, Cilt: 29 - Sayı: 3, 305–334. https://ajindex.com/articles/637300

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. 2015 Türkiye Kanser istatistikleri. Ankara:
  2. T.C. Sağlık Bakanlığı, Halk Sağlığı Genel Müdürlüğü, 2018 2. Abedalthagafi M, Phillips JJ, Kim GE, Mueller S, Haas-Kogen DA, Marshall RE, Croul SE, Santi MR, Cheng J, Zhou S, Sullivan LM, Martinez-Lage M, Judkins AR, Perry A: The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: A multi-institutional study of 214 astrocytomas. Mod Pathol 26:1425-1432, 2013 3. Akyerli CB, Yuksel S, Can O, Erson-Omay EZ, Oktay Y, Cosgun E, Ulgen E, Erdemgil Y, Sav A, von Deimling A, Gunel M, Yakicier MC, Pamir MN, Ozduman K: Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. J Neurosurg 128(4):1102-1114, 2018 4. Alcantara Llaguno SR, Parada LF: Cell of origin of glioma: Biological and clinical implications. Br J Cancer 115:1445- 1450, 2016 5. Alcantara Llaguno SR, Wang Z, Sun D, Chen J, Xu J, Kim E, Hatanpaa KJ, Raisanen JM, Burns DK, Johnson JE, Parada LF: Adult lineage-restricted CNS progenitors specify distinct glioblastoma subtypes. Cancer Cell 28:429-440, 2015 6. Amirian ES, Armstrong GN, Zhou R, Lau CC, Claus EB, Barnholtz-Sloan JS, Il’yasova D, Schildkraut J, Ali-Osman F, Sadetzki S, Johansen C, Houlston RS, Jenkins RB, Lachance D, Olson SH, Bernstein JL, Merrell RT, Wrensch MR, Davis FG, Lai R, Shete S, Amos CI, Scheurer ME, Aldape K, Alafuzoff I, Brannstrom T, Broholm H, Collins P, Giannini C, Rosenblum M, Tihan T, Melin BS, Bondy ML: The glioma international case-control study: A report from the genetic epidemiology of glioma international consortium. Am J Epidemiol 183:85-91, 2016 7. Amirian ES, Zhou R, Wrensch MR, Olson SH, Scheurer ME, Il’yasova D, Lachance D, Armstrong GN, McCoy LS, Lau CC, Claus EB, Barnholtz-Sloan JS, Schildkraut J, Ali-Osman F, Sadetzki S, Johansen C, Houlston RS, Jenkins RB, Bernstein JL, Merrell RT, Davis FG, Lai R, Shete S, Amos CI, Melin BS, Bondy ML: Approaching a scientific consensus on the association between allergies and glioma risk: A report from the glioma international case-control study. Cancer Epidemiol Biomarkers Prev 25:282-290, 2016 8. Bai H, Harmanci AS, Erson-Omay EZ, Li J, Coskun S, Simon M, Krischek B, Ozduman K, Omay SB, Sorensen EA, Turcan S, Bakirciglu M, Carrion-Grant G, Murray PB, Clark VE, ErcanSencicek AG, Knight J, Sencar L, Altinok S, Kaulen LD, Gulez B, Timmer M,